Crizotinib derivative as well as preparation method and application thereof
A technology of crizotinib and its derivatives, applied in the field of new anti-tumor drugs, to achieve the effect of improving anti-tumor activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0022]
[0023] Compound (II-a) (1.35g, 3mmol) was added into a 100mL flask and dissolved in 40mL of acetonitrile, phenylisothiocyanate (III-a) (0.446g, 3.3mmol) was added, and reacted at 25°C for 12h. The product (I-a) was obtained by filtration with a yield of 86%.
[0024] 1 H NMR (500MHz, CDCl 3 )δ13.40(s, 1H), 8.89(s, 1H), 7.90(d, J=1.8Hz, 1H), 7.71(d, J=7.6Hz, 2H), 7.64(s, 1H), 7.57( s, 1H), 7.41(t, J=7.9Hz, 2H), 7.18(d, J=7.4Hz, 1H), 7.14(d, J=7.6Hz, 2H), 7.10(d, J=1.8Hz, 1H), 6.18(m, J=6.7Hz, 1H), 4.64(d, J=7.5Hz, 2H), 4.46-4.37(m, 1H), 3.35-3.21(m, 2H), 2.29-2.18(m , 2H), 2.20-2.06(m, 2H), 1.93(d, J=6.7Hz, 3H). 13 C NMR (126MHz, CDCl 3 )δ184.02,178.19,142.40,140.02,139.77,138.81,136.33,135.74,133.15,129.37,128.72,126.17,125.33,124.71,123.50,123.37,122.53,118.99,117.30,117.10,116.18,73.37,58.60,51.13 , 48.47, 44.48, 31.73, 18.86.
Embodiment 2
[0026]
[0027] Add compound (II-a) (1.35g, 3mmol) in 100mL flask and dissolve in 40mL acetonitrile, add isothiocyanate plus p-methylphenylisothiocyanate (III-b) (0.439g, 3.3mmol ), reacted at 60°C for 8h. The product (I-b) was obtained by filtration with a yield of 87%.
Embodiment 3
[0029]
[0030] In a 100mL flask, compound (II-b) (1.39g, 3mmol) was added and dissolved in 40mL of dichloromethane, p-chlorophenylisothiocyanate (III-c) (0.560g, 3.3mmol) was added, and Reaction at 80°C for 6h. The product (I-c) was obtained by filtration with a yield of 78%.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


